Role of metabolomics in identifying cardiac hypertrophy: an overview of the past 20 years of development and future perspective

Expert Rev Mol Med. 2021 Aug 11:23:e8. doi: 10.1017/erm.2021.12.

Abstract

Cardiac hypertrophy (CH) is an augmentation of either the right ventricular or the left ventricular mass in order to compensate for the increase of work load on the heart. Metabolic abnormalities lead to histological changes of cardiac myocytes and turn into CH. The molecular mechanisms that lead to initiate CH have been of widespread concern, hence the development of the new field of research, metabolomics: one 'omics' approach that can reveal comprehensive information of the paradigm shift of metabolic pathways network in contrast to individual enzymatic reaction-based metabolites, have attempted and until now only 19 studies have been conducted using experimental animal and human specimens. Nuclear magnetic resonance spectroscopy and mass spectrometry-based metabolomics studies have found that CH is a metabolic disease and is mainly linked to the harmonic imbalance of glycolysis, citric acid cycle, amino acids and lipid metabolism. The current review will summarise the main outcomes of the above mentioned 19 studies that have expanded our understanding of the molecular mechanisms that may lead to CH and eventually to heart failure.

Keywords: Cardiac hypertrophy; NMR spectroscopy; left ventricle hypertrophy; mass spectrometry; metabolomics; right ventricle hypertrophy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiomegaly* / diagnosis
  • Humans
  • Magnetic Resonance Spectroscopy
  • Metabolic Networks and Pathways
  • Metabolomics*
  • Myocytes, Cardiac